financetom
Business
financetom
/
Business
/
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
Aug 29, 2024 9:32 AM

11:10 AM EDT, 08/28/2024 (MT Newswires) -- Dick's Sporting Goods' (DKS) fiscal Q2 earnings are expected to top analyst estimates, but a "material deceleration" in trends in H2 is likely to limit a potential upside for its shares, Wedbush said in a note Wednesday.

"Growth is being led by the company's mid-upper income customer demographic skew, differentiated and better access to on-trend products, 'cascading' customer service and other processes from House of Sport to the rest of the chain, and omnichannel initiatives," the investment firm said in its Q2 preview note.

Wedbush also expects the company to raise its fiscal 2024 guidance "by a similar amount that it did just three months ago," driven primarily by the anticipated Q2 beat. The company is scheduled to release its Q2 results on Sept. 4.

However, the firm said the "beat-and-raise quarter" is unlikely to spur excitement among investors as it sees "a material deceleration from [H1] trends against tougher comparisons and the reversal of the calendar shift benefit."

Wedbush is staying neutral on the stock even as it raised its price target to $250 from $230.

Price: 233.97, Change: -2.33, Percent Change: -0.99

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Mar 16, 2026
08:13 AM EDT, 03/16/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered a clinical supply agreement with Johnson & Johnson ( JNJ ) to evaluate investigational drug MRT-2359 in combination with Erleada in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will sponsor...
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
Mar 16, 2026
08:12 AM EDT, 03/16/2026 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said Monday a Phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%. Patients receiving the 10-milligram per kilogram dose demonstrated an estimated median progression-free survival of 7.1 months, the company said. The 8.6-milligram per kilogram cohort...
Copyright 2023-2026 - www.financetom.com All Rights Reserved